Research & Technology

Current Difficulties in Cancer Treatment

Cancer continues to be the leading cause of death, responsible for one in three fatalities. Despite advancements, existing cancer immunotherapies, like CAR-T, have significant limitations:

• Single Target Focus: Most therapies are designed to attack only one target, which is often not specific to cancer cells alone.

• Ineffectiveness Against Solid Tumors: Current treatments struggle to effectively combat solid tumors, which include cancers of tissues such as pancreatic, lung, breast, and liver. These types make up 90% of all cancer cases.

• Low Remission Rates: Even with targeted approaches like CAR-T, remission rates are disappointingly low, below 20%. For instance, the 5-year survival rate for pancreatic cancer is only about 8.5%.

The analogy for current treatments is akin to having a key for just one lock while cancer cells possess many. When we attempt to unlock one with our single key, the cancer cell uses its multitude of other locks to remain secure and evade destruction.

In stark contrast, EagleImmune's technology aims to be among the first market offerings capable of effectively treating solid tumors, refractory cancers, and recurrent cancers, introducing a new era of multi-targeted immunotherapy.Advancing Cancer Treatment with EagleImmune.

EagleImmune's patented technology, the Aggregated-Immune-Reprogramming-Platform (AIRP), revolutionizes cancer treatment by modifying therapeutic immune cells to enhance their capabilities against cancer. These AIRP-enhanced T cells are reintroduced into the patient, where they diligently hunt down and eliminate cancer cells, particularly those forming solid tumors. Unlike traditional methods, these reprogrammed cells don't just strike once; they maintain a vigilant, ongoing presence, continuously generating more cancer-combating cells

AIRP technology effectively addresses the challenges posed by cancer's heterogeneity, mutagenicity, and evasive tactics. By transitioning from a single-target approach to a multi-target strategy, AIRP acts like a master key, capable of unlocking multiple cancer-specific locks simultaneously, thereby effectively dismantling solid tumors.

EagleImmune's multi-targeted cancer technology marks a significant advancement in immunotherapy, with the goal of unlocking new possibilities for life through groundbreaking cancer treatment innovations.